[1] Campbell DJ,Koch MA. Phenotypic and functional specialization of FOXP3+regulatory T cells[J].Nat Rev Immunol,2011,11(2):119-130.[2] Cheng M,Chen Y,Xiao W,et al. NK cell-based immunotherapy for malignant diseases[J]. Cell Mol Immunol,2013,10(3):230-252.[3] 郑全辉,刘英文,张雪梅. 肺癌小鼠MDSC和T细胞变化[J].中国免疫学杂志,2015,31(5):595-599.[4] Patel S,Vetale S,Teli P,et al.IL-10 production in non-small cell lung carcinoma patients is regulated by ERK,P38 and COX-2[J]. J Cell Mol Med,2012,16(3):531-544.[5] Shi W,Li X,Cha Z,et al.Dysregulation of circulating follicular helper T cells in nonsmall cell lung cancer[J]. DNA Cell Biol,2014,33(6):355-360.[6] Reppert S,Boross I,Koslowski M,et al.A role for T-bet-mediated tumour immune surveillance in anti-IL-17A treatment of lung cancer[J].Nat Commun,2011,2:600.[7] Duan MC,Han W,Jin PW,et al. Disturbed Th17/Treg balance in patients with non-small cell lung cancer[J]. Inflammation,2015,38(6):2156-2165.[8] 邹 静,刘 斌,陈雪华,等.肺癌患者外周血T淋巴细胞亚群变化特点及其临床意义[J].中国免疫学杂志,2010,26(11):1016-1020.[9] 张瑞萍,徐冰心,王社论,等. 晚期非小细胞肺癌调节性T细胞与预后的关系[J]. 现代肿瘤医学, 2013,21(3):521-524.[10] 赵 霞,韩福才,苏 文,等. 晚期肺癌患者外周血Treg细胞与NK细胞及其活化受体检测临床意义的探讨[J].中华肿瘤防治杂志,2011,18(13):1009-1012.[11] 侯玉森,苏 文,王艳峰,等.肺癌患者调节性T细胞与NK细胞活化受体NKG2D的相关性及其临床意义[J]. 肿瘤研究与临床,2012,24(9):597-599.[12] Zhang Q,Furukawa K,Chen HH,et al. Metastatic potential of mouse Lewis lung cancer cells is regulated via ganglioside GM1 by modulating the matrix metalloprotease-9 localization in lipid rafts[J]. J Biol Chem,2006,281(26):18145-18155.[13] Wang P,An F,Zhuang X,et al. Chronopharmacology and mechanism of antitumor effect of erlotinib in Lewis tumor-bearing mice[J].PLoS One,2014,9(7):e101720.[14] Lindau D,Gielen P, Kroesen M,et al. The immunosuppressive tumour network:myeloid-derived suppressor cells,regulatory T cells and natural killer T cells[J].Immunology,2013,138(2):105-115.[15] Hall BM,Verma ND,Tran GT,et al. Distinct regulatory CD4+T cell subsets;differences between naïve and antigen specific T regulatory cells[J]. Curr Opin Immunol,2011,23(5):641-647.[16] Wieland E,Shipkova M. Lymphocyte surface molecules as immune activation biomarkers[J].Clin Biochem,2016,49(4/5):347-354.[17] Feng LL,Wang X. Targeting foxp3+ regulatory T cells-related immunosuppression for cancer immunotherapy[J].Chin Med J (Engl),2010,123(22):3334-3342.[18] Makkouk A,Weiner GJ. Cancer immunotherapy and breaking immune tolerance:new approaches to an old challenge[J]. Cancer Res,2015,75(1):5-10. |